Pfizer Inc (PFE) Q3 2024 Earnings Report

Pfizer Inc (PFE) reported robust financial results for the third quarter of 2024, showcasing a notable revenue of $17.7 billion, reflecting a 32% operational growth compared to the prior year. The company's strategic focus on oncology and recent product launches fueled enhanced sales across key therapeutic areas, contributing to an impressive net income of $4.465 billion or EPS of $0.78. With continued momentum from COVID-19 products and a diversified portfolio, Pfizer is well-positioned to drive future growth. Management has raised 2024 revenue guidance, highlighting confidence in sustained performance and operational excellence. In the earnings call, CEO Albert Bourla emphasized the strong execution and market share gains in both U.S. and international markets, reiterating the company's commitment to delivering breakthroughs that significantly impact patients' lives. Management's forecast includes a full-year revenue guidance adjustment to between $61 billion and $64 billion, driven by solid sales performances from both COVID and non-COVID products, with operational revenue growth expected to remain in the range of 9% to 11%.